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Abstract
A laboratory-based surveillance study of adult invasive pneumococcal disease was conducted in North-Rhine Westphalia, Germany’s
most populous federal state, with approximately 18 million inhabitants. Invasive isolates (n = 519) were obtained between 2003 and
2006, before the general recommendation for vaccination of German children <2 years with the pneumococcal conjugate vaccine
was issued at the end of July 2006. Penicillin G resistance was observed in 5% of meningitis cases. In the non-meningitis group, only
intermediately resistant strains were detected (0.4%). Intermediate resistance to cefotaxime occurred both in meningitis cases (1.7%)
and non-meningitis cases (0.4%). Non-susceptibility rates (intermediate resistance and resistance) were 16.2% for macrolides, 10.9% for
trimethoprim–sulphamethoxazole, 5.0% for tetracycline, 3.9% for clindamycin, and 0.4% for levoﬂoxacin. All isolates were susceptible to
amoxycillin (non-meningitis) and telithromycin. The leading serotypes were serotypes 14 (14.3%), 7F (9.4%), 3 (9.2%), 4 (8.7%) and 1
(8.1%). Serotype coverage for the seven-valent conjugate vaccine was 43.9%. For the ten-valent and 13-valent vaccines (in development),
the coverages were 61.8% and 76.7%, respectively. The 23-valent polysaccharide vaccine had a coverage of 91.1%.
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Introduction
Streptococcus pneumoniae is a leading cause of bacterial pneu-
monia, sepsis and meningitis among adults worldwide [1].
Mortality rates associated with invasive pneumococcal dis-
ease (IPD) vary from 5% to 35%, depending on the site of
infection, comorbidity, and patient age [2]. Globally, the
prevalence of antibiotic-resistant S. pneumoniae continues
to increase [3,4]. In Europe, especially France, Spain, and
eastern European countries are concerned [5], and outside
Europe, such as in South Africa, non-susceptibility rates of
up to 79% have been reported [6].
In Germany, pneumococcal vaccination (23-valent poly-
saccharide vaccine) is recommended for elderly adults
(‡60 years) and individuals with underlying high-risk factors
[7]. Pneumococcal conjugate vaccination in Germany was
ﬁrst recommended for high-risk children (indication-based)
in 2001, and at the end of July 2006 it was generally
recommended for children <2 years of age [8]. A previous
study by our group monitored the serotype distribution
and antibiotic susceptibilities in the subgroup of hospital-
ized adults in North-Rhine Westphalia for the years 2001–
2003, and calculated the under-reporting and estimated
incidence of IPD [9]. Nevertheless, whereas the predomi-
nance of certain serotypes has been well recognized
among children, for adults the amount of data is consider-
ably lower.
The present study analyzes the serotype distribution,
coverage of pneumococcal vaccines and antimicrobial sus-
ceptibilities of all S. pneumoniae isolates obtained from
inhabitants ‡16 years of age with IPD and sent to the
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German National Reference Centre for Streptococci
(NRCS) during the last 3 years before the general recom-
mendation for pneumococcal conjugate vaccination for
children <2 years of age.
Materials and Methods
Study design
The NRCS has conducted surveillance for invasive pneu-
mococcal disease in Germany for several years. In the cur-
rent study, a laboratory-based approach was used to
collect data on invasive pneumococcal disease in adults in
North-Rhine Westphalia, the most populous federal state
in Germany, with approximately 18 million inhabitants.
State residents ‡16 years of age were included in the
study. A case of IPD was deﬁned by the isolation of
S. pneumoniae from a normally sterile site. In cases of
unclear invasiveness, samples were considered to represent
invasive disease only after a review of all available labora-
tory information, specimen type, physician’s specialty, and
comments on request forms. The study started in 2001.
Initial results on serotype distribution and antibiotic sus-
ceptibilities in the subgroup of hospitalized adults in
North-Rhine Westphalia for the years 2001–2003 have
already been published, as well as calculations of under-
reporting and estimated incidence of IPD [9]. Now, data
from the period 1 July 2003 to 30 June 2006 are
reported.
Microbiological investigations
All isolates were identiﬁed by standard procedures, includ-
ing bile solubility and optochin sensitivity. MIC testing was
performed using the broth microdilution method as rec-
ommended by the CLSI [10]. Macrolide resistance was
investigated using erythromycin or clarithromycin, and
erythromycin was replaced by clarithromycin over the
years. S. pneumoniae ATCC 49619 was used as a control
strain. Current CLSI interpretative criteria were used to
deﬁne antimicrobial resistance [10]. According to the new
guidelines, different breakpoints for the parenteral use of
penicillin concerning meningitis and non-meningitis cases
have to be applied. In non-meningitis cases, the new
breakpoints for susceptible, intermediate and resistant are
£2 mg/L, 4 mg/L, and ‡8 mg/L, respectively. For meningitis
cases, no intermediate category exists; isolates are catego-
rized as susceptible (£0.06 mg/L) or resistant (‡0.12 mg/L).
Pneumococcal isolates were serotyped by Neufeld’s Quel-
lung reaction, using type-speciﬁc and factor-speciﬁc antisera
(Statens Serum Institut, Copenhagen, Denmark).
Results
A total of 519 isolates from adult invasive pneumococcal
disease were collected between 1 July 2003 and 30 June 2006.
The numbers of included cases for each epidemiological year
(1 July to 30 June) were: 2003–2004, 174; 2004–2005, 146;
and 2005–2006, 199. The isolates were obtained from blood
(450), cerebrospinal ﬂuid (41), pleural ﬂuid (16), bronchoalve-
olar lavage ﬂuid (seven), synovial ﬂuid (two), peritoneal ﬂuid
(two), and other specimens (three). The gender distribution
was nearly equal. Only a few more isolates were obtained
from female patients (50.5%) than from male patients (48.7%),
and for 0.8% no information on gender was available. The
male/female ratio (male cases/female cases) depended on the
age group, as follows: 16–30 years, 13/5; 31–40 years, 26/17;
41–50 years, 35/10; 51–60 years, 39/28; 61–70 years, 65/51;
71–80 years, 55/78; and >80 years, 20/73. No prominent
differences concerning serotype distribution in these age
groups could be observed (data not shown).
The serotype distribution is shown in Table 1. The leading
serotypes were serotypes 14 (14.3%), 7F (9.4%), 3 (9.2%), 4
(8.7%), and 1 (8.1%). Serotype coverage for the seven-valent
TABLE 1. Serotype distribution of invasive pneumococcal
disease isolates in North-Rhine Westphalia, Germany (2003–
2006)
Serotype
2003–2004 2004–2005 2005–2006 2003–2006
n % n % n % n %
14 21 12.1 28 19.2 25 12.6 74 14.3
7F 22 12.6 11 7.5 16 8.0 49 9.4
3 18 10.3 15 10.3 15 7.5 48 9.2
4 11 6.3 14 9.6 20 10.1 45 8.7
1 16 9.2 6 4.1 20 10.1 42 8.1
9V 8 4.6 11 7.5 13 6.5 32 6.2
23F 5 2.9 13 8.9 11 5.5 29 5.6
6B 10 5.7 5 3.4 8 4.0 23 4.4
19A 3 1.7 2 1.4 13 6.5 18 3.5
22F 4 2.3 5 3.4 7 3.5 16 3.1
11A 8 4.6 2 1.4 3 1.5 13 2.5
18C 6 3.4 3 2.1 4 2.0 13 2.5
19F 4 2.3 3 2.1 5 2.5 12 2.3
6A 5 2.9 2 1.4 4 2.0 11 2.1
8 3 1.7 3 2.1 5 2.5 11 2.1
9N 5 2.9 3 2.1 2 1.0 10 1.9
10A 2 1.1 5 3.4 2 1.0 9 1.7
12F 6 3.4 1 0.7 1 0.5 8 1.5
17F 3 1.7 2 1.4 2 1.0 7 1.3
33A 0 0.0 2 1.4 5 2.5 7 1.3
20 1 0.6 3 2.1 2 1.0 6 1.2
33F 2 1.1 1 0.7 1 0.5 4 0.8
Othersa 11 6.3 6 4.1 15 7.5 32 6.2
Total 174 100.0 146 100.0 199 100.0 519 100.0
n, number of isolates tested.
aOthers include the following types (no. of isolates 2003–2006): 9A (three), 10B
(three), 24F (three), 38 (three), 5 (two), 15B (two), 19C (two), 31 (two), 9L
(one), 15C (one), 15F (one), 35C (one), 18F (one), 23A (one), 23B (one), 13
(one), 18A (one), 17A (one), 37 (one), and rough (one).
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conjugate vaccine was 43.9%. For the ten-valent and
13-valent vaccines (both in development), the coverages
were 61.8% and 76.7%, respectively. The 23-valent polysac-
charide vaccine had a coverage of 91.1% (Table 2).
Detailed results of the susceptibility testing are shown
in Table 3. Penicillin G resistance was observed in 5% of
meningitis cases. In the non-meningitis group, only intermedi-
ately resistant strains were detected (0.4%). One hundred
per cent of isolates were susceptible to amoxycillin (non-
meningitis). For cefotaxime, only intermediate resistance
occurred in meningitis (1.7%) and non-meningitis cases
(0.4%). Overall non-susceptibility rates (intermediate resis-
tance and resistance) were 16.2% for macrolides, 3.9% for
clindamycin, 0.4% for levoﬂoxacin, 5.0% for tetracycline, and
10.9% for trimethoprim–sulphamethoxazole. All isolates
were susceptible to telithromycin.
Discussion
In this article, we present the results of 3 years of surveil-
lance of adult invasive pneumococcal disease in North-Rhine
Westphalia, Germany, directly prior to the recommendation
for general pneumococcal conjugate vaccination for children
<2 years of age. The overall gender distribution was nearly
balanced (female, 50.5%; male, 48.7%; no information on
gender available, 0.8%), similar to results published earlier
[5,11]. Interestingly, males are more often affected in the
16–70-year age group, whereas females contract IPD more
often in the ‡71-year age group, probably as a result of the
longer life-expectancy of women.
In the present study, serotype 14 was the most prevalent
serotype, followed in frequency by serotypes 7F, 3, 4, and 1,
respectively. Although comparable data concerning children
<16 years of age have been published recently [12], few data
concerning the serotype distribution of IPD in adults have
been published so far, and, in particular, recent data are rare.
In a previous study from the NRCS [9], conducted among
hospitalized state residents in North-Rhine Westphalia from
1 July 2001 to 30 June 2003, serotype 14 was the most fre-
quent serotype (15.6%) as well. The next most frequent ser-
otypes were serotypes 3 (9.3%), 4 (7.1%), 7F (6.6%), and 23F
(5.9%). This serotype distribution is similar to that in other
countries, published previously [11,13–15].
An evaluation of changes in the serotype distribution of IPD
isolates, obtained from adults in the USA between 1928 and
1998, revealed an increasing proportion of infections caused
by serotypes included in the seven-valent conjugate vaccine,
TABLE 2. Coverage of invasive pneumococcal disease sero-
types in North-Rhine Westphalia, Germany, by pneumococ-
cal vaccines (2003–2006)
Vaccine type
Coverage (%)
2003–2004 2004–2005 2005–2006 2003–2006
7-valent 37.4 52.7 43.2 43.9
10-valent 59.2 64.4 62.3 61.8
13-valent 74.1 77.4 78.4 76.7
23-valent 90.8 93.2 89.9 91.1
Vaccine strains included are as follows. Seven-valent: serotypes 4, 6B, 9V, 14,
18C, 19F, and 23F. Ten-valent: seven-valent serotypes plus serotypes 1, 5, and
7F. Thirteen-valent: ten-valent serotypes plus serotypes 3, 19A, and 6A.
Twenty-three-valent: ten-valent serotypes plus serotypes 2, 3, 8, 9N, 10A, 11A,
12F, 15B, 17F, 19A, 20, 22F, and 33F.
TABLE 3. Antibiotic susceptibilities of invasive pneumococcal disease isolates from North-Rhine Westphalia, Germany (2003–
2006)
2003–2004 2004–2005 2005–2006 2003–2006
CLSI breakpoints
(mg/L)
n I% R% n I% R% n I% R% n I% R% I R
Penicillin G, meningitis 22 0.0 0.0 24 0.0 8.3 14 0.0 7.1 60 0.0 5.0 – ‡0.12
Penicillin G, non-meningitis 150 0.0 0.0 122 0.0 0.0 185 1.1 0.0 457 0.4 0.0 4 ‡8
Amoxycillin, non-meningitis 150 0.0 0.0 122 0.0 0.0 185 0.0 0.0 457 0.0 0.0 4 ‡8
Cefotaxime, meningitis 22 0.0 0.0 24 0.0 0.0 14 7.1 0.0 60 1.7 0.0 1 ‡2
Cefotaxime, non-meningitis 150 0.0 0.0 122 0.8 0.0 185 0.5 0.0 457 0.4 0.0 2 ‡4
Macrolidesa 172 0.0 12.8 146 0.0 22.6 199 0.0 14.6 517 0.0 16.2 0.5 ‡1
Clindamycin 172 0.0 2.3 146 0.0 5.5 199 0.0 4.0 517 0.0 3.9 0.5 ‡1
Tetracycline 172 0.6 2.9 146 0.7 4.8 199 0.0 6.0 517 0.4 4.6 4 ‡8
Telithromycin 172 0.0 0.0 146 0.0 0.0 199 0.0 0.0 517 0.0 0.0 2 ‡4
Levoﬂoxacin 100 0.0 0.0 146 0.7 0.7 198 0.0 0.0 444 0.2 0.2 4 ‡8
Trimethoprim–sulphamethoxazole 99 6.1 6.1 145 4.8 4.8 198 4.5 6.6 442 5.0 5.9 1/19–2/38 ‡4/76
n, number of isolates tested; I, intermediately resistant; R, resistant. MIC breakpoints according to CLSI M100-S18 [10], 2008.
aMacrolides: erythromycin or clarithromycin.
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from 15% to 59%, while, by contrast, the proportion of infec-
tions caused by the ‘epidemic’ serotypes (1–3 and 5)
decreased signiﬁcantly from 71% to 7% [16]. Discussion of the
reasons for this has focused on historical changes in serotype
distribution, changes in socio-economic conditions, antibiotic
use, immunocompromised status of populations, increased
life-expectancy, and blood culture practices [11,16]. Further-
more, signiﬁcant regional variations among serotypes have
been described [5,11]. All are of importance when the effects
of vaccination programmes and related changes in serotype
distribution are interpreted, and highlight the need to use
actual data from comparable regions for interpreting changes
in the context of vaccination programmes.
Serotype coverage for the seven-valent conjugate vaccine
in North-Rhine Westphalia was 43.9%. This is very similar to
the 39.9% coverage reported from Barcelona, Spain [17].
Calculated coverages for the ten-valent and 13-valent vac-
cines (both in development) are 61.8% and 76.7%, respec-
tively. Interestingly, as compared with 2001–2003 [9], there
was an increase in the frequency of the additional vaccine
candidate serotypes 1 (2001–2003, 5.1%; 2003–2006, 8.1%),
7F (6.6%; 9.4%), and 19A (1.1%; 3.5%), which might be of
interest for future vaccination programmes. The 23-valent
polysaccharide vaccine in our study had a coverage of 91.1%,
which is within the usually reported range of 80% to ‡90%
[9,15,18,19].
The epidemiology of antibiotic-resistant S. pneumoniae
varies greatly between countries and continents [20,21]. In
Europe, high resistance rates for penicillin have been
reported from Spain, France, and eastern European coun-
tries, whereas Germany and the northern European coun-
tries are only marginally affected [5]. According to the
current CLSI guidelines [10], different breakpoints must be
applied for penicillin G with regard to meningitis and non-
meningitis cases. Under these conditions, the rate of penicil-
lin resistance among the non-meningitis cases is remarkably
low (<1% non-susceptibility), whereas the rate of resistance
in meningitis cases is higher (5.0% on average).
Macrolides showed the highest rate of resistance among
the antibiotics tested in the present study. More than 15% of
IPD isolates were resistant, which is in agreement with
results previously reported from Germany [9,22], but is still
within the lower range of non-susceptibility in an inter-
national context [6]. Tetracycline non-susceptibility (5.0%) is
lower than previously reported for invasive pneumococcal
disease in Germany (1992–2000, 11.7%; 2001–2003, 7.1%)
[9,22]. Marked differences among pneumococcal isolates
have been reported worldwide, and especially high non-
susceptibility rates of up to 81.6% are found in Asia [6,21].
Although increasing rates of ﬂuoroquinolone resistance have
been described in some previous reports, especially for
Hong Kong and Korea, but also for Canada, the USA,
Mexico, and Japan, the rate of resistance remains relatively
low worldwide [21,23–27]. While levoﬂoxacin resistance
was very low or absent in other European countries, in
Germany the level of levoﬂoxacin non-susceptibility detected
(0.4%) has remained at the same level as recorded in 2001–
2003 [26].
The present study describes the current status of IPD in
adults in North-Rhine Westphalia, Germany, and may serve
as a basis for the interpretation of potential changes con-
cerning the effects of pneumococcal childhood vaccination
programmes on IPD in adults, especially on serotype
distribution, resulting coverages of current vaccines and vac-
cines in development, as well as their potential effects on
antibiotic resistance of S. pneumoniae.
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